黄色软件免费观看_日本韓國三級國產歐美_在线综合亚洲欧美首页_手机看免费黄色毛片_黄色三级视频_国产 刺激 男女视觉盛宴_在线精品无码字幕无码αv_亚洲香蕉久久国产精品_温客行X周子舒车肉干_日韓歐美一區二區三區免費觀看

Entries by

EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER’S DISEASE IN GREAT BRITAIN

Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a Marketing Authorization Application (MAA) for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer’s disease with confirmed amyloid pathology in the brain, to the UK Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. Lecanemab has been designated by the MHRA for the Innovative Licensing and Access Pathway (ILAP).

HEALTH CANADA ACCEPTS NEW DRUG SUBMISSION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER’S DISEASE

TOKYO and CAMBRIDGE, Mass., May 16, 2023 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (brand name in the U.S.: LEQEMBI?), an investigational anti-amyloid beta (Aβ) protofibril* antibody, for the treatment of early Alzheimer’s disease (mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD dementia) with confirmed amyloid pathology in the brain.

Feng Yanhui, President of Eisai China, visited SINOPHARM Holding Henan

Feng Yanhui, President of Eisai China, visited SINOPHARM Holding Henan Co., Ltd for business research, accompanied by Li Yunlong, VP of Eisai China, Zhao Jianjun, Director of North China Access Department, and Xia Ruiying, Manger of North China Access Department in Eisai China. Chen Zhanyu, Vice President of SINOPHARM Holding and Chairman of SINOPHARM Holding Henan, Zhang Zhaohui, General Manager of SINOPHARM Holding Henan, Xu Hai, Deputy General Manager of SINOPHARM Holding Global Procurement and Supply Chain Service Center , Li Jie, Assistant General Manager of SINOPHARM Holding Henan, and Yang Fan, Director of Supply Chain Business Development Department of SINOPHARM Holding received Feng Yanhui and her delegation.

EISAI ENTERS INTO JOINT DEVELOPMENT AGREEMENT WITH BLISSBIO FOR ANTIBODY DRUG CONJUGATE BB-1701 WITH OPTION RIGHTS FOR STRATEGIC COLLABORATION

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into a joint development agreement with Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (Headquarters: Zhejiang Province, China, “BlissBio”), for BB-1701, an antibody-drug conjugate (ADC) with option rights for a strategic collaboration.